^
Association details:
| Biomarker: | POLE mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Bavencio (avelumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor
Excerpt:
Meet at least one of the following requirements; A. PD-L1 positive by IHC or B. EBV positive by ISH or C. MSI-H by IHC or D. POLE mutation E. POLD1 mutation
Trial ID:
